Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our noninvasive laser pulse oximetry line, including Nico and HemeOx continues progressing positively |
| We expect consistent growth and strong financial performance in 2024, following the double-digit growth we have produced year after year |
| We believe both offer attractive return profile |
| Once again, we received the highest number of prescriptions in company history, exceeding our previous record |
| I'm proud to announce that we also produced a $17.8 million in positive cash from operations in 2023, another all-time record for the company |
| In the fourth quarter, orders increased 29% year-over-year to the highest number of orders in company history for the seventh consecutive quarter |
| We're pleased with our performance this quarter and the consistent growth our team is delivering |
| Significant credit goes to our team who were able to drive revenue higher and deliver significant earnings per share and free cash flow as we expand our sales force, invest in our new business, Zynex monitoring and combat wage inflation like many others in the business |
| Our sales force has continued to expand the market each quarter, enabled by a strong team and great products |
| And with the continued growth in orders in the first quarter, I can tell you we're off to a good start |
| We believe there is considerable runway for us to continue growing orders into the future, leveraging our current portfolio and growing pipeline of existing and new and exciting new products |
| We are incredibly proud of the growth that we have consistently demonstrated in the past several years |
| Top line revenue has produced high levels of profitability and free cash flow, which has allowed us to expand our sales force, launch a new business line to diversify our revenue stream and continue repurchasing our shares |
| 2023 was highlighted by ongoing revenue momentum, leading to a record revenue for the year of $184 million, up 17% from the prior year |
| We expect that building a successful stand-alone fluid monitoring market will take longer than other new monitoring products, but we believe strongly in the benefits patients will experience and the value proposition provided by the technology |
| Zynex's Pain Management division had another impressive quarter with 29% order growth and 43% order growth for the full year |
| We are looking to leverage this management team's past success at building businesses to grow a second line of products with a much larger market opportunity at comparable profitability |
| So it is looking very positive |
| Our production group has done a really good job with pricing here |
| In addition to the impressive results from our profitable pain management division, our monitoring - Zynex monitoring solutions, the monitoring division continued to move forward in the fourth quarter with further development of our blood and fluid monitor and our laser-based pulse oximeter. |
| We believe both these avenues will produce substantial shareholder value |
| Overall, we are making great progress in the patient monitoring division, which we believe will have a game-changing growth potential for the company |
| We also expect additional catalysts and regulatory milestones during the year as we work to execute on our strong pipeline of new products |
| We are rapidly expanding direct sales distribution channels that are delivering accelerating and high returning revenue - high recurring revenue as we continue to execute operationally and strategically |
| The continuing buyback reflects our belief in the management team, the growth opportunities for both divisions, and we remain committed to creating shareholder value in the near and long term |
| We continue to have strong relationships with our payers |
| Orders increased 43% for the full year compared to the year before an increased 29% year-over-year in the fourth quarter |
| We've had a strong start to the first quarter |
| So we would expect to continue to see those strong margins into '24 and beyond |
| The fourth quarter marked our 11th consecutive quarter of profitability and seventh straight quarter of record high order numbers |
| Statement |
|---|
| During the fourth quarter, we played an allowance of $6.2 million on accounts receivables, which decreased our net revenue and profitability |
| We added a net of approximately 60 sales reps during the year, which decreases the growth in revenue per rep in the near term as those reps ramp up |
| And as the sales force got more effective in the back half of '22, those got a little tougher |
| I would say that we don't expect the growth to slow down on the NexWave |
| I would say margins we expect to stay constant or slightly expand a little bit |
| Zynex has the technologies and strategies necessary to make a successful entrance into the new product line and market, but the process of acquiring FDA clearance can be somewhat lengthy with occasional delays |
Please consider a small donation if you think this website provides you with relevant information